| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Alesse Approved For Sale In Canada MONTREAL, QC -- January 28, 1998 -- Canada's Health Protection Branch has approved Wyeth-Ayerst's low-dose contraceptive Alesse, which offers women a new birth control option with an improved side-effect profile. In clinical trials, less than one percent of participants discontinued using the product due to weight gain, acne or other commonly-cited side effects. In the 1995 Canadian Contraception Study, 73 percent of women identified weight gain as the major side effect of oral contraceptives. Other than the desire to get pregnant, most women have cited side effects as the number one reason why they stop taking the birth control pill. In the survey, 50 percent of Canadian women said side effects or concern about side effects were the reason for discontinuing the pill. Alesse contains two female sex hormones – estrogen (ethinyl estradiol) and progestin (levonorgestrel). The drug contains a low amount of estrogen while maintaining the optimum ratio of the estrogen to progestin. When taken as directed, Alesse has been proven to be 99 per cent effective. As with other birth control pills, Alesse may additionally provide protection from ovarian cancer, endometrial cancer and pelvic inflammatory disease. Alesse is available in a 21-day fand a 28-day dosage regimen. The product should not be used by women with a history of heart attack or heart disease, liver disease, breast cancer or abnormal vaginal bleeding. Cigarette smoking increases the risk of serious cardiovascular side effects. More information on: Alesse, Wyeth-Ayerst
|